Scientists find the molecule mechanism of psoriasis
According to a study published in EMBO Reports, scientists have discovered how CARD14 mutations lead to inflammation in psoriasis patients. The results suggested that MALT1 inhibitors might be used as a treatment for those who have CARD14 mutations. (Cusabio offers high-quality products of protein, gene, antibody and kit. http://www.cusabio.com/Chemokine/Recombinant-Human-C-C-motif-chemokine-18-proteinCCL18-11098401.html)
Psoriasis is an autoimmune disease that affects the skin and joints. There are a large number of people who suffer from psoriasis in the world. Patients with the disease often have red scaly patches on their skin. Unfortunately, there is no cure for the disease although there are therapies to keep it under control. People who have particular mutations in the CARD14 gene are more likely to develop psoriasis.
In psoriasis, the activation of the immune system leads to local inflammation and proliferation of skin cells. CARD14 mutations can make the CARD14 protein more capable of activating another protein that regulates the production of some factors that promote skin inflammation and psoriasis.
To explore the molecular mechanism of psoriasis, the research team looked at keratinocytes, a kind of skin cells that are involved in the disease. They found that CARD14 can activate another protein, known as MALT1. The MALT1 protein cleaves and inactivates a number of cellular proteins that normally keep the immune system in check. Furthermore, CARD14 mutations lead to the formation of hyperactive CARD14/MALT1 complexes, which induce strong immune responses and inflammation.
The team also found that drugs that block MALT1 activity decreased the levels of inflammation promoting proteins that are caused by CARD14 mutations. The findings offered possibilities to use MALT1 inhibitors to treat psoriasis.